ASCO 2020 | DARS: dysphagia-optimised intensity-modulated radiotherapy

Christopher Nutting, BSc, MBBS, MD, PhD, FRCP, FRCR, MedFIPEM, of the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK, discusses the DARS study, a randomized phase III trial aiming to reduce dysphagia post-radiotherapy treatment by using dysphagia-optimised intensity-modulated radiotherapy (Do-IMRT). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).